OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
April 05, 2022
Lonza has joined IPAC-RS, providing benefits to Lonza’s inhalation- related businesses due to IPAC-RS’ global voice of the orally inhaled and nasal drug products industry.
February 01, 2022
CDMOs offer expertise and capacity for spray drying.
October 15, 2021
Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery.
September 13, 2021
When designing and manufacturing a pMDI or DPI combination drug-delivery device, the commercial stage should be kept in mind from the beginning of development.
August 27, 2021
FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension.
August 01, 2021
The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.
July 03, 2021
Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.
July 01, 2021
Vectura will provide preclinical development services for Incannex’s inhaled drug product for the treatment of traumatic brain injury.
March 10, 2021
The expansion plans to increase Vectura’s DPI dosage form development, specifically its unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs.
September 02, 2020
Creating an inhaled formulation is one way in which improved efficacy or added value can be achieved in projects to repurpose or reposition existing drugs.